AMPICILLIN FOR INJECTION, USP POWDER FOR SOLUTION

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

AMPICILLIN (AMPICILLIN SODIUM)

Prieinama:

FRESENIUS KABI CANADA LTD

ATC kodas:

J01CA01

INN (Tarptautinis Pavadinimas):

AMPICILLIN

Dozė:

250MG

Vaisto forma:

POWDER FOR SOLUTION

Sudėtis:

AMPICILLIN (AMPICILLIN SODIUM) 250MG

Vartojimo būdas:

INTRAMUSCULAR

Vienetai pakuotėje:

10 ML

Recepto tipas:

Prescription

Gydymo sritis:

AMINOPENICILLINS

Produkto santrauka:

Active ingredient group (AIG) number: 0105872002; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

1998-01-06

Prekės savybės

_____________________________________________________________________________________________
Ampicillin for Injection, USP_ _– Prescribing Information
Page 1 of 10
PRESCRIBING INFORMATION
INCLUDING PATIENT MEDICATION INFORMATION
PR
AMPICILLIN FOR INJECTION, USP
Powder for solution
250 mg, 500 mg, 1 g and 2 g per vial
For Intramuscular or Intravenous Use
STERILE
ANTIBIOTIC
FRESENIUS KABI CANADA LTD.
Date of Preparation:
165 Galaxy Blvd, Suite 100 August 16, 2019
Toronto, ON M9W 0C8
CONTROL NUMBER: 223388
_____________________________________________________________________________________________
Ampicillin for Injection, USP_ _– Prescribing Information
Page 2 of 10
PRESCRIBING INFORMATION
PR
AMPICILLIN FOR INJECTION, USP
Powder for solution
Sterile
PHARMACOLOGICAL CLASSIFICATION
Antibiotic
ACTIONS AND CLINICAL PHARMACOLOGY
Ampicillin
has a broad spectrum of bactericidal activity against many
gram-positive
and gram-
negative aerobic and anaerobic bacteria. It acts through the
inhibition
of cell wall mucopeptide
biosynthesis during the stage of active multiplication.
INDICATIONS AND CLINICAL USE
The treatment of infections
due to susceptible
gram-negative
organisms
(including
strains of
_Shigellae_, _ S. typhosa_ and other
_salmonellae, E. coli_, _ H. influenzae_, and _ P. mirabilis_) and
susceptible
gram-positive
organisms
[including
streptococci,
pneumococci,
and
non-beta-
lactamase (penicillinase) producing staphylococci].
To reduce the development of drug
‐
resistant bacteria and maintain the effectiveness of Ampicillin
for Injection,
USP and other antibacterial
drugs, Ampicillin
for Injection,
USP should
be used
only to treat infections that are proven or strongly suspected to be
caused by susceptible bacteria.
When culture and susceptibility
information
are available, they should be considered in selecting
or
modifying
antibacterial
therapy.
In
the
absence of
such
data,
local
epidemiology
and
susceptibility
patterns may contribute to the empiric selection of therapy.
CONTRAINDICATIONS
A history of alle